A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC)

Category Systematic review
JournalJ. Clin. Oncol.
Year 2020
This article has no abstract
Epistemonikos ID: 051e00edd8f964a2503d2e30fcec8b6cf5b71321
First added on: Mar 20, 2020